Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Zanapezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zanapezil SCHEMBL1232176 | 1.00 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203739 | 0.99 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203761 | 0.99 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9200365 | 0.97 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9200378 | 0.97 | ACHE (0.91) | ACHE | |
| Zanapezil SCHEMBL678642 | 0.95 | ACHE (1.00) | ACHE | |
| Zanapezil SCHEMBL29366424 | 0.95 | ACHE (1.00) | ACHE | |
| SCHEMBL9204959 | 0.95 | ACHE (1.00) | ACHE | |
| Fumaric Acid SCHEMBL9206740 | 0.94 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9206750 | 0.94 | ACHE (0.91) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144255-A1 | Compositions for prevention and treatment of dementia | BAIN ALLEN I (CA) | 2003-07-31 | — | — | US | claimed |
| US-6500820-B1 | Pharmaceutical composition for neurotrophic action | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-31 | — | — | US | claimed |
| EP-0952826-B1 | IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| WO-2001066096-A2 | COMPOSITIONS FOR PREVENTION AND TREATMENT OF DEMENTIA | IMMUNE NETWORK LTD. (CA) | 2001-09-13 | — | — | WO | claimed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | claimed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | claimed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-0610854-B1 | Tablets with improved abrasion resistance and method to produce them | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999053909-A2 | PHARMACEUTICAL COMPOSITION FOR NEUROTROPHIC ACTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| US-5456920-A | Tablet containing active ingredient, excipient, oily or fatty substance having relatively low melting point; improved abrasion resistance | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0610854-A1 | Tablets with improved abrasion resistance and method to produce them | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ACHE 765/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ACHE 403/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ACHE 765/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ACHE 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.